Amylin gets FDA OK for weekly diabetes drug Bydureon

Say hello to Bydureon, a once-weekly injectable treatment for Type 2 diabetes finally approved by the FDA on Jan. 27. Amylin Pharmaceuticals ($AMLN) developed the drug using controlled release drug delivery technology supplied by Alkermes ($ALKS). Amylin is billing the drug as the "first and only" weekly Type 2 diabetes treatment approved to date by the FDA, versus the standard twice-daily injections. Bydureon consists of biodegradable microspheres, which release a controlled amount of the drug over 7 days. Regulators previously rejected Bydureon twice before. Release | Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.